News & events

# Zentia spotlight

Financial results, clinical milestones and conference presentations — the latest from across the company.

Media inquiries → Investor presentation
Zentia Reports Third Quarter 2026 Financial Results and Business Updates
Financial results

August 12, 2026

### Q3 2026: strong progress across the ASPENOVA Phase 3 program

Enrollment continues across global sites, with operating guidance updated following the advancement of our registration-intent programs.

Read the release →

All news

## Latest headlines

Aug 12, 2026
Financial results

### Zentia Reports Third Quarter 2026 Financial Results and Business Updates

Company progress on the ASPENOVA Phase 3 program and continued enrollment across late-stage trials.

→
Jun 24, 2026
Clinical trial

### First Patient Dosed in the ASPENOVA Phase 3 Trial in Cyclin E1-Positive Ovarian Cancer

Global enrollment begins for the first oral, biomarker-driven approach in this patient population.

→
May 18, 2026
Conference

### Zentia to Present New Clinical Data at the ESMO Congress 2026

Updated safety and efficacy data from our ongoing clinical programs will be featured this year.

→
Apr 09, 2026
Clinical trial

### Phase 2 Data Support Biomarker-Defined Strategy in Uterine Serous Carcinoma

Updated findings reinforce the companion diagnostic and registration-intent design.

→
Feb 26, 2026
Corporate

### Zentia Expands Manufacturing Partnership for Oral Formulation

New supply agreement supports commercial readiness as late-stage programs advance.

→
Feb 10, 2026
Financial results

### Zentia Provides Full-Year 2025 Financial Results and 2026 Outlook

Capital position expected to fund operations through key registration milestones.

→
Jan 22, 2026
Conference

### Zentia to Present at the J.P. Morgan Healthcare Conference

Executive team to discuss pipeline progress and 2026 priorities with investors.

→